INmune Bio Inc.

Stand by, your program is about to begin. Greetings and welcome to the ImmuneBio Third Quarter 2024 earnings call. As a reminder, this conference is being recorded. A transcript will follow within 24 hours of this conference call. At this time, it is my pleasure to introduce Mr. David Moss, CFO of ImmuneBio. David.

Thank you Chloe and good afternoon everyone. We thank you for joining us for the call for ImmuneBio Third Quarter 2024 financial results. With me on the call today are Dr. RJ Tessie, CEO and co-founder of ImmuneBio, Dr. Mark Liddell, Chief Scientific Officer and co-founder of ImmuneBio, and Dr. CJ Barnum, our head of neuroscience. Before we begin, I remind everyone that except for statements of historical facts, the statements made by management and responses to questions on this conference call are forward-looking statements under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those such as forward-looking statements. Please see the forward-looking statements disclaimer on the company's earnings press release, as well as the risk factors in the company's SEC filings, including our most recent quarter filing with the SEC. There's no assurance of any specific outcome. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made as the facts and circumstances underlying these forward-looking statements may change. Except as required by law, ImmuneBio disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances. With the forward-looking statements behind us, it's now my pleasure to turn the call over to Dr. RJ Tessie. RJ.

Thank you, David, and good afternoon to everyone.

For

our

third quarter 2024 call, I will review the key takeaways and provide an update on our platform programs. Following my review of recent developments at ImmuneBio, I will pass the microphone to Dr. CJ Barnum, who runs our CNS development efforts, for updates on the Alzheimer's program and the treatment resistant depression program. Then I will pass it to Dr. Mark Liddell, a founder and in the new bio CSO and the mentor of Incmean,

who will

provide an update on the care PC Incmean program and metastatic castrate resistant prostate cancer. David will include our prepared remarks with a review of our financial results for the third quarter, after which we will be happy to take your questions. First and foremost, we announced that we closed enrollment to our ADO2 global blinded randomized phase two trial of Expro in patients with Alzheimer's disease and biomarkers of inflammation. This milestone was reached on September 27th and symbolizes a major achievement for our team. This was a huge and visible milestone that really overshadowed the incredible work that was required to get there. The complexity of managing a clinical trial in countries with

30 sites

force us to work fast, smart and efficiently. In doing so, our team demonstrated remarkable perseverance by successfully navigating the complex regulatory landscapes outside of the US. Despite the many hurdles, we are delivering a program that has been conducted with the highest quality standards. And we've had some very couple of very careful reviews of the trial to ensure that this continues. This experience may provide or should provide preparation for a global phase three study that will most likely include more countries and more sites in the Alzheimer's program.

The achievement

not only underscores our commitment to advancing our program in AD, but can translate to our other programs in treatment resistant depression, prostate cancer and beyond. Furthermore, we are confident that the data we are generating in our diverse international sites will provide robust insights into extra sufficiency and safety profile. And I emphasize the critical safety profile in patients with early Alzheimer's disease. Well, X pro is our most advanced program. It is not the only clinical asset at immune bio and community, a novel and K focused cancer programs currently enrolling patients with metastatic cast rate resistant prostate cancer in a phase one to trial. We call this open label trial care PC. We have been recently enrolled the first patient into the highest dose cohort. That is the highest of three dosing cohorts and are also enrolling patients into the phase two extension portion of the middle dose cohort. This is a Bayesian design that allows you to do overlap the phase one phase two parts of the trial.

Results

from the first low dose cohort were released late in September and showed consistent immunologic effects in the NK cell compartment and confirms the excellent safety profile, which we've come to expect from that. In coming in, you're not underestimate the importance of the safety when treating men with metastatic cast rate resistant prostate cancer. The average age of men in the US with MCR PC is 76 years old and these patients become increasingly frail as their disease progresses. Patients and clinical teams are looking for effective therapies that do not cause significant toxicities. So far, in community meets that low toxicity threshold. We look forward to better understanding efficacy as we continue to treat patients at the higher doses. The program was introduced to the prostate cancer community last weekend at the 31st annual scientific meeting of the Prosthetic Cancer Foundation, a meeting that includes important clinical leaders in the US prostate cancer community. The program was well received. Mark Liddell will provide a more in depth report on InCMUNE in a few moments. But for now, I'd like to turn it over to CJ Barnum, who leads immune bio CNS drug development efforts. He will provide more details on our ongoing phase two trial and our soon to be started treatment for this depression trial.

CJ.

Thank

you, RJ.

I'm here to provide an update on our ex pro clinical programs and outline what lies ahead in the coming months. I will start with our phase two Alzheimer's study. The primary objective of ADO2 is to demonstrate that patients treated with ex pro exhibit improved cognitive function compared to those receiving placebo. As reported last month, enrollment has been completed. During this critical phase between the last patient enrolled and the release of top line data, our clinical team is diligently focused on data collection and preparation to expedite the delivery of these crucial results. Notably, our third party vendors have continually highlighted two exceptional aspects of this trial. The superior quality of data collection and the outstanding performance of our primary endpoint, EMAC, which has surpassed our expectations and its ability to measure cognitive change in patients with early Alzheimer's disease. While we're thrilled about EMAC's potential, it's important to know that ADO2 is powered by the clinical dementia rating scale sum of boxes. This key secondary cognitive endpoint has served as a primary endpoint and been instrumental in gaining approval for all three anti-AMOE phase three trials. Empowering the study on the CDR, we mitigate risks in the regulatory pathway by providing a second well validated cognitive endpoint. To provide further insights into EMAC and our regulatory strategy, we will be hosting a webinar on November 7th. Our NeuroCyte consultants will lead the discussion and you can expect additional details about the webinar shortly. On a parallel track, our operations team is making significant progress in launching our phase two trial for treatment resistant depression. We anticipate opening the first site by the end of the year. This blinded, randomized, placebo controlled, NIH funded study will enroll 90 patients with biomarkers of inflammation. Participants will receive expel or placebo over the course of six weeks. The primary endpoint is change in functional MRI within a brain pathway that subserves depression and inflammation. This trial will also measure clinical scales that will provide the critical data necessary to conduct a future proof of concept study. We look forward to sharing more updates on this trial and future calls. Thank you and I'll turn it back over to RJ.

Thank you, CJ. With that, I'll turn the

microphone over to Mark to discuss the InCMUNE program. Mark.

Thank you, RJ. And good afternoon, everyone. Thank you for joining the call. So as RJ said, the CARE-PC trial continues to recruit completely in line with our predicted timeline. We now have opened the phase two extension of the intermediate dose cohort, which allows a further six patients to receive this dose of InCMUNE in the Bayesian design that RJ described. The first of these six extension patients were already identified and have begun screening. There is a queue, apparently, of patients awaiting treatment. Meanwhile, the first patient in the high dose group was enrolled this week and will receive his first treatment on the 5th of November. We expect to complete treatment of all patients in this high dose group during January 2025 and then progress immediately to the phase two extension for further six patients in February and March at the highest dose. Monitoring of the immune response to inpatients in the intermediate cohort is underway and results will be communicated as soon as they're available. As RJ said, we saw InCMUNE related changes in NK cell function in the first three patients at the lowest dose, with increases in activated NK cells in the peripheral blood and the generation of increased potency of these NK cells in tumor killing assays. So we're eagerly awaiting the data from the second dose cohort, which we'll be keen to share. We see metastatic castrate resistant prostate cancer as the first of many solid tumor targets for InCMUNE, and we've recently completed our preclinical study of renal cell cancer as a potential trial group. This adds to our preclinical data in ovarian cancer, B-cell lymphoma, and other blood cancers, and allows us to consider multiple options for future clinical development of this drug. Clinical trials are the poster children of drug development, but moving from trials to market requires much more, not least a full development of the drug manufacturing pathway, which meets regulatory requirements and is cost effective at a scale which meets the likely global demand. ImmuneBio is laser focused on this rather less glamorous aspect of drug development, allowing delighted a report that we've made significant progress in what's called the chemistry, manufacturer, and control, or CMC, aspects, and scaled up manufacturer flyfold with associated cost efficiencies, but more work to further simplify manufacturer is also underway. All of the drug doses for the phase one and intermediate phase two extension are in stock and ready for shipment, and many are already in the United States, and we will complete manufacture of the remainder of the current trial products before the end of this year. We've drug stability data to support over two years of storage at our US distribution facility and up to one month local storage at clinical sites. And we've worked with our clinical sites to engineer the drug delivery to the clinical team and the infusion protocols to make this the most easily delivered cellular medicine in the world, and I say that from many, many years of many trials of cellular medicines. If CarePC provides the efficacy data we hope, then Inkmune will be ready for commercial manufacture for future drug registration trial and subsequent BLA submission. So that ends my update of the Inkmune platform, and I'd like to turn the call over to David Moss, our CFO, to discuss the financials. David?

Thank you, Mark, RJ, and CJ. As usual, I'll provide a brief overview of our financial results and upcoming milestones before we head to our Q&A session. During our third quarter, we're pleased to have raised $13 million in gross proceeds from a registered direct equity offering. In total, the company issued in aggregate approximately 2.3 million shares of common stock and warrants in aggregate of about 2.3 million shares of common stock. The warrants have a five and a half year term with the potential acceleration pursuant to the terms of the warrant agreement, which if exercised would raise additional capital. I'll note that the company has approximately 3.9 million warrants outstanding and the ability to all be accelerated, and this would raise just north of 30 million if it were to occur. In the financing, management and employees and members of the board, directors purchased about $800,000 from the stock. Cannot underscore how financially committed and aligned the entire Inkmune Bio team is to the success of the company. We also greatly appreciate the support we saw in the offering from both new and existing investors, along with our team here at Inkmune Bio. Now moving on to the financials. Net loss attributable to common stockholders for the quarter ended September 30th, 2024 was approximately 12.1 million, compared with approximately 8.6 million for the comparable period in 2023. Research and development expenses totaled approximately 10.1 million for the quarter ended September 30th, 2024, compared with approximately 6 million for the period, the comparable period in 2023. General and administrative expenses were approximately 2.2 million for the quarter ended September 30th, 2024 compared with approximately 2.6 million for the comparable period in 2023. At September 30th, 2024, the company had cash and cash equivalents of approximately 33.6 million. Based on our current operating plan, we believe our cash is sufficient to fund our operations into Q3 of 2025. As of October 31st, 2024, the company had approximately 22.2 million shares of common stock outstanding. Now I'd like to focus on some key upcoming milestones. We expect to have top line cognitive data from our Phase 2 trial in Alzheimer's disease in Q2 of 2025. We will initiate a Phase 2 trial of ExPro in patients with treatment resistant depression, as CJ had mentioned, towards the end of this year. We expect to complete enrollment in the third cohort of the metastatic castration resistant cancer, prostate cancer program, as Mark had mentioned, around January of 2025, and complete the Phase 2 portion is expected to be completed either in Q2, Q3 of 2025. Results from the trial will be released as they become available. Although we have secured additional funding, as always, we continue to focus on achieving our primary clinical objectives while remaining cost prudent with the potential to recover a portion of R&D expenses in Australia and the UK. We will have further paid off our Silicon Valley bank debt on December 1st of this year, which will help reduce our quarterly spend. I'll also note that in the beginning of next year, we should start to see sites wind down in the ADO2 program and do expect some of those costs to get lower. In summary, we secured a meaningful equity infusion recently that puts us in good position into 2025, and we're focused on the execution of our programs. At this point, I'd like to turn the microphone back to RJ to conclude our prepared remarks. RJ?

Thank

you, David. I'd like to wrap up our prepared remarks by saying we are busy. It is heads down at ImmuneBio as we work towards data in our mindful Phase 2 in Alzheimer's disease and our CARE PC trial in metastatic castrate resistant prostate cancer. We hope to open another chapter in our DNF story with the Phase 2 in treatment resistant depression before our next quarterly call. We have strong science backing our Ketting Edge programs and may provide unique solutions to difficult medical problems and have the money funding to see them through important milestones. We appreciate our strong and committed shareholder base, and we all thank you for investing alongside us as we work to achieve our goals. Operator, I'd like to poll for questions.

Certainly, at this time, if you would like to ask a question, please press the star and one on your telephone keypad. You may withdraw yourself from the queue at any time by pressing star two. And once more for your questions, that is star and one. We'll take our first question from Gary Nockman with Raymond James. Your line is open.

All right, great. Thanks guys. Good afternoon and congrats on the progress. So a few questions first. In the expert Phase 2 in Alzheimer's, when you think of how selective you've been with patient enrollment, looking for the right inflammatory biomarkers, talk about what that process has been like. And would it be a challenge if you end up moving to a bigger Phase 3 down the road or even when you think about ex pro commercially? So start with that and then have a couple of follow ups.

Yeah, let me start and then I'm sure CJ will have some something to add to my comments. This is RJ. So as you know, this was a really based on two things, Gary, and we've been very transparent about this one. We believe that matching the mechanism of ex pro, which is targeting glial activation and neuroinflammation with the patient's disease is important to allow us to de-risk the clinical program. So we are focused on patients that have inflammation driving their Alzheimer's disease. And that turns out to be in Caucasians, probably about 50% of patients. And let me give you a good example. One of the biomarkers we use APOE4. And I'm here in Madrid at the CTAD meeting, which is a large clinically focused Alzheimer's meeting. And virtually every trial that is presented, 50% of the patients have APOE4. So I'm very comfortable saying we are targeting 50% of the patients. And you know, for a small company to have a strategy that de-risk the clinical trial so we can gain success early is we're willing to accept 50% of a large market. Now, the regulatory issue is a different question. And I think that we have some ideas, but this will be a major topic of discussion at I'm sure at the end of phase two meeting with the FDA. I do not expect, you know, I don't know what to predict that will be, but we'll be able to manage around it. I'm confident. CJ, anything you want to add there?

I'll ask Gary, and maybe I'm, if I don't quite answer your question, please correct me. I think the simple answer is, and RJ is right, is I don't think the biomarker is going to be a major issue as we move into phase three and beyond, because there are plenty of patients with APOE4. And I think that's probably the bigger issue as I look at the data compared to

the inflammatory stuff. Okay, that's helpful.

And then I think you send the press release. If you still have patients that are already screened, that'll end up enrolling at some point. Just could that push out the timing of the data readout potentially to later in 2Q given the 24 week endpoint? So just confirm, you know, within 2Q that we should be thinking about that. I don't know whether the first half or the second half. And then just also remind us of your confidence in a 24 week endpoint on the EMACS score, given some challenges that we've seen in other Alzheimer's studies when they look out six months.

Yeah, well, let me start with the length. I mean, one of the things that I noted at the meeting is we're seeing a lot more short trials. And when I say short, I mean not 18 months, which is 76 weeks. We've seen a raft of 48 week trials. We've seen some six month trials and, you know, people are designing trials smarter and so they can be short. We have been very loud in our claims that, you know, we're very comfortable with a six month endpoint. So we're not concerned there. And we actually believe the more the field is really kind of waking up to the fact that 18 month trials are are not necessary. Particularly if you know the mechanism of action of your drug. You're right. We are there are some patients in screening. There's a few extra patients who are in the screening process. You know, we're not going to cut a patient off who's in the screen that that. And say you can't be involved after they've already made the commitment to the program. So the drop dead date is about 10 days from now that, you know, everyone will have been wrung out of the system by that point. So I think you can start thinking about the clock from that perspective. I mean, David and I and I think CJ have mentioned that, you know, we expect data in Q2 and we are quite comfortable with that with that claim. But it requires CJ's operational clinical operations team to be, you know, working 24 seven to make sure the data is clean, correct. And so we can lock

the database and publish the results quickly. Okay, great.

And then just last question, RJ, a bigger picture. So, with the news of that, be acquiring for 1.4 billion to have an early stage. Thought on goal and Alzheimer's, how does that impact your thinking about potential in this space? If at all, you know, how it might be evolving and. Just on that, you know, have you been having any potential partnership discussions, you know, just sort of what the interest level is out there. Thanks.

Yeah, well, I'm going to really pair it with David. And what Mark says every time anyone talks to him is that we strongly believe that everybody's waiting for data since we're not walking down the amyloid or cow path, which is where most of the M&A has been occurring. They they are are really buying assets that they consider de risk. I can tell you all of the anti amyloid programs. I predict we'll have similar efficacy profiles. The safety profiles may be different, but, you know, those drugs do an excellent job of getting rid of amyloid from the brain and we know what the results are. So we believe that once we show that targeting glial activation makes a difference. People will be starting conversations and, you know, we, you know, we people, the phone rings every once in a while, but they're really very. You know, the way how is the weather kind of calls? We have no real deep seated. Business development discussions in place and quite frankly, it goes back to what I said that David always says it's all about data

when

we get data.

People will talk. Okay, great. Thanks guys.

We'll move next to George farmer with Scotiabank. Your line is open.

Hi, good afternoon. Thanks for taking the questions. I was wondering if you comment on. Your depression study that you're gearing up to do, and you mentioned some inflammatory biomarkers that you're going to be screaming for as well. Are these the same as the ones in Alzheimer's disease or are they different? To the extent that you can talk about them, that would be great. And then I have a follow up.

Okay.

Yeah, thanks. Great question. Thanks for asking. This is, this is the program that I'm really excited about. So the simple answer to that is yes, we are enriching for patients that have inflammation. And this is based on really well researched studies, both in the clinic with the animal data support by a group at every university that's led by Andy Miller and Jen Felger. So we have two biomarkers that we're using. One is blood C reactive protein. And the other one is a behavioral biomarker of anedonia. So anedonia is a core symptom of depression. And that for those of you that don't know what anedonia is, it's the lack of pleasure, of deriving pleasure and things that you enjoy. It's a very difficult symptom to treat. And it is tied tightly regulated with inflammation. So we will be selecting patients based on those two inflammatory biomarkers. And again, we expect that about somewhere between 45 and 55% of patients will meet criteria for those biomarkers. And by the way, you'll see this consistent theme across any program that we start is that the inflammatory biomarkers somewhere around 40 to 50%. So those are the two key biomarkers associated with

that. Okay, great. Very interesting. And then a question on Incommune. What do you need to see in this trial to really give you confidence that continued investment is worthwhile? Specifically, you talk about reductions in PSA, which is great. But have you seen any impact on measurable tumors? And do you need to see that in order to move forward with this program?

Mark, you want to go ahead? Yeah, yeah, thank you. So, first of all, it's a phase one trial. So we're treating very, very advanced stage patients with very bulky disease. So from an immunological perspective, what I want to know is that we're changing their ability to make an immune response against their tumor, because that means that moving it into a better risk patient group in further drug development is indicated because we know from other research that patients with good NK responses have a better prognosis. With with prostate cancer with this particular group, we because we've got the the PSMA PET scans, we are able not only to look at their total tumor load, but to look at individual tumors within the within the individual patients. And that I think is going to be very informative. We've probably got some evidence already that some tumors do shrink while others are growing. So basically what I'm looking for is any form of a clinical outcome that convinces Matt Rettig as the chief investigator that there's been a clinical response and it really falls to him to believe in the data. So it'll be data that he he's able to say, yes, that convinces me we're having a clinical response.

All

right, and if I could

just add, just add one comment and I want to go back to the safety bit. You know, one of the things Matt Rettig has said, who spends his life treating these men. Is that, you know, having a therapy that significantly prolongs life, even if you don't completely eradicate the tumor, but you prolong life with a good quality of life is a very important metric in this patient group, because, you know, all of the, a lot of the metastatic castor programs are really targeting the subset of patients that are below the meat age. So they're in their late fifties or early sixties, and I already mentioned that the median age of seventy six. So, in fact, a lot of patients really don't get much care because they can't tolerate the toxicity of this of the more traditional regimen. So, you know, we, I keep coming back to the safety profile. If we see the kind of immunologic effects and and and tumor effects that we're expecting, this is going to be really attractive for a big segment of the

prostate cancer community. All right, thanks.

I'll move next to Joel with Baird. Your line is open.

Okay, hi, team. Thanks for the update and congrats on finishing enrollment in the phase two Alzheimer's disease trial. Maybe first question is earlier this summer, you shared a favorable interim analysis of the trial. Any changes in the trial or operations since then, that would lead to any differences since that time.

She's good.

Thanks, Joel. So,

I'm not sure I completely understand your question, but I think I can let me take a stab at it. There are no changes as it relates to the interim data analysis. If anything, what we've done is we've continued to follow that. And you're going to hear more about that on the webinar. So I'll sort of state the comments for next week. But so I'm not sure if I have your question. Answered correctly. Yeah,

I think you're getting at it. I guess I'm asking is in the enrollment that has occurred since the interim analysis, would the data such as the variance or data collection be expected to be any different? I don't know if the enrollment criteria of patients might be different since that time of the interim.

Yeah, just okay. Understood. So we've so the answer is no, we haven't changed the overall criteria hasn't changed it. But as we get more data, actually, what we're seeing are better numbers. And again, well, this is going to be described in more detail in the webinar. But the answer, the short answer is, is yes, it's.

It's the

more data we get, the better

it looks.

Very good. Yeah, I look forward to more on the on the webinar. And then I guess maybe a question on Inc. You know, it's been highlighted in the past on the call today that it's can be the most easily delivered cellular medicine in the world. Could you elaborate more on the delivery and I think you kind of now and as it might look in the future.

Mark. Yeah, certainly. Yeah. So if you think about other, you know, better known cellular medicines like car T cells, virtually every one of them is shipped in, I think, or a dry shipper in vapor phase nitrogen, minus 160 degrees centigrade or below. And then when they get into hospitals, they have to go through a special handling route. And so, quite often they delivered direct to the patient bedside and that's not the route that most drugs go into hospital. Every other drug comes in through pharmacy and is held in pharmacy and then issued from pharmacy to go to the patient. And so we've we've done a lot of work from get go to make immune immune fit into that. So it comes in at minus 80 like like COVID vaccines. It goes into a minus 80 freezer. And since COVID every pharmacy has many, many, many of those. And then when it goes to the patient bedside, it goes in a toolbox, rather than in nitrogen and gets stored in an automated thawing device that we have developed that we buy in. But the program for thawing has been developed by us. And it's a bit like a microwave. It goes in that it's the lid's closed. And when it's ready, it detects that the thawing has been done. It goes ping and there's no then there's no washing thereafter. The bag gets hooked up like any other chemotherapy type bag and is delivered through a peristaltic pump. So the nurses like it because it's exactly what they're familiar with using in these patients. Patients like it because there's nothing scary about it. There isn't a vapor phase of nitrogen gases coming off and lots of lots of vapor spilling around their bed. And this is meant to be delivered in the outpatient setting. So these patients don't even have to be hospitalized. And we've been able to go into veterans hospitals in the US which are not delivering CAR T therapies and other cellular medicines. So we really have nailed the delivery of this, the local storage and a temperature that fits in with other drugs and makes it very easy and therefore cost effective. So that's what we meant about that. We've tailored the delivery to fit in with routine clinical practice of other regular medicines that are not cellular medicines.

And if I can just re

-emphasize the point Mark made that this does not need to be used in centers that are used to giving cellular medicines. This can be given in any infusion site. And in fact, our first two patients were treated at sites that were commercial sites that had never given a cellular medicine. And Mark and his team have videos and training tools

for

them. And this group was of the nursing and the staff of the pharmacy and nursing staff. I mean, it was, you know, went through it and they were very comfortable and things have gone perfectly well. So it's really, really user friendly. It's patient friendly. And now we're waiting to hopefully show that it's not so friendly to the cancer and helps clear the patient's disease. But that will take a little bit more time

to

determine.

Thank you.

We'll move next to Tom Schrader with BTIG. Your line is open.

Good afternoon. I wanted to return to the TRD area because we never really talk about that. How have you thought, I know it's early, but about commercialization of an injectable drug in the TRD setting? And I guess specifically, is this something that could go into the ketamine clinics? Is the delivery close enough that the infrastructure will have been built for you?

And I have a follow up. CJ? Yeah, I can answer that. I

would not put this in the category of ketamine. I think this is going to be more like an insulin shot, you know, an injectable that the patients will be able to take home and do by themselves. So I think this is a qualitatively different process. And there are other drugs and psychiatric disease that are injectable, perhaps not so much as in depression. But for the patients that we're going to be targeting, which are these treatment resistant or these inflamed depressions, these are the ones that typically have more severe disease. Whereas, you know, people have more mild disease, you know, maybe they're more inclined to try a pill first. But I don't think we're going to have any issues with the injectables. And when you talk to some of the clinicians that treat this and you ask that specific question, they don't even give it two thoughts. So I think it, you know, obviously it remains to be seen how it plays out. But at this point, we don't think we'll have any issues.

So it's an auto-injectable infusion. Correct. Yeah, it's the same as what we give for the AD patients. Yeah.

And then one more sort of slightly wacky CJ question. Does inflammation play a role in the psychedelics? Is that known? Seems like it easily could given all the changes going on.

You know, I don't have, I don't have, I'm not ready for that answer. I'd have to spend some time. I apologize. I don't know. Yeah, no, that's okay. It's a very psychedelic question.

Now,

if

I

can just tutorialize on your on your subcuke on your delivery question, Tom, I can remember many years ago when we first started and there was considerable concern about the fact that this was a subcutaneous injection. And I think one of the big advantages of GOP revolution and obesity is everybody is completely comfortable now with subcutaneous delivery of drugs. And so, you know, in fact, if you look at both both at Lilly with the Nanomab, they're moving to a subcute formulation for their anti-amyloid drugs. I mean, it's just, you know, it's infusions

are

a hurdle.

Everything else the patients can manage. All right, got it. Thanks for all the thoughtful answers.

And we'll move next to Matthew with a AGP. Your line is open.

Hey, guys, this is Matt on for Jim. Congratulations on the progress for the quarter. Just one question. Would you would you guys be able to provide a little more color on the 2.5 mil R&D rebate from Australia and what that can or has been spent on program wise?

Sure.

Yeah, so we

yeah, yeah, yeah. Appreciate the question, Matt. So we run a lot of our operations through Australia and Australia has an incentive program where you can get up to 44 cents back on every Australian dollar you spend over there. And you can convert that into an actual cash rebate. So you'll next year, you'll expect that number to be quite a bit higher than what we received the last time. And then also in the UK, we get a smaller amount. They've kind of paired the program back a bit. But because our income program has been expanding in the UK, mainly on the manufacturing front and the work that's done over in Mark's group, that rebate also will be going back up again. So it kind of it was large in the UK. They changed the program. It went almost to zero. And now it's let's just say it's probably about 20 to 30 percent of what it was historically. So we'll be able to get more money back from the UK. So does that help answer your question? And all of the R&D rebate that we got out of Australia is related to the ADO2, mostly the ADO2 program. Got

it. Yeah. And then that is, are there any restrictions on how you spend that or that's just a cash rebate?

It's just a cash rebate. It's a benefit for doing R&D in Australia. Got it. Thank you guys. And there are no restrictions. We can spend, you know, we just reinvest that really into our clinical program.

Understood. So that's one of the reasons going forward it will reduce part of our burn. Do you have like

any estimate in terms of how much it would reduce the burn? You did say it was going to increase in coming quarters, the rebates.

Yeah, it varies. I'd say for, you know, just to be conservative going forward, I would use like a four million dollar number for next year. It would probably be higher than that. But I would be very conservative and say four at this point.

Gotcha. Thank you.

And it does appear that there are no further questions at this time. I would now like to turn it back to R.J. for any closing remarks.

Yeah, thank you, operator. So our website now has 88 scientific publications and 12 different diseases. A fresh example of that cutting edge science that drives our programs was added a few days ago when Leslie Probert, leading an international team of scientists published an important work on how X-Pro promotes remyelination. The work was published in the journal cell reports. This is timely and relevant to our clinical programs in neurodegenerative diseases. With the success of our funding raise, we now have the capital to complete both our trial and early Alzheimer's disease and our phase one incrium trial and prostate cancer. And these programs are making very positive headway. Our aim is to provide positive readouts for both those programs that have been so that the concept of these new strategies is well received by clinicians, regulators, investors and potential partners. Providing new solutions to difficult clinical problems is why we're all here today. And our goal is to make patients and investors proud of our accomplishments. We appreciate your support. Thank you for listening to the call.

This does conclude today's program. Thank you for your participation. You may disconnect at any time and have a wonderful afternoon.